Search hospitals > California > Santa Monica
UCLA Hematology Oncology - Santa Monica
Claim this profileSanta Monica, California 90404
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Solid Tumors
Conducts research for Tumors
91 reported clinical trials
7 medical researchers
Summary
UCLA Hematology Oncology - Santa Monica is a medical facility located in Santa Monica, California. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Solid Tumors, Tumors and other specialties. UCLA Hematology Oncology - Santa Monica is involved with conducting 91 clinical trials across 82 conditions. There are 7 research doctors associated with this hospital, such as Zev A. Wainberg, Sara Hurvitz, MD, Jonathan W. Goldman, and Saeed Sadeghi.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR
Top PIs
Zev A. WainbergUCLA2 years of reported clinical research
Expert in Solid Tumors
Studies Pancreatic Cancer
32 reported clinical trials
64 drugs studied
Sara Hurvitz, MDUCLA Medical Center / David Geffen School of Medicine2 years of reported clinical research
Expert in Breast Cancer
Studies Tumors
17 reported clinical trials
24 drugs studied
Jonathan W. GoldmanUCLA / Jonsson Comprehensive Cancer Center5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
12 reported clinical trials
19 drugs studied
Saeed SadeghiUCLA Medical Center10 years of reported clinical research
Studies Bile Duct Cancer
Studies FGFR2 Mutation
6 reported clinical trials
8 drugs studied
Clinical Trials running at UCLA Hematology Oncology - Santa Monica
Breast Cancer
Non-Small Cell Lung Cancer
Solid Tumors
Pancreatic Cancer
Cancer
Tumors
Colorectal Cancer
Lung Cancer
Squamous Cell Carcinoma
Prostate Cancer
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
CoREST Inhibitor + Anti-PD-1 Therapy
for Solid Cancers
This trial is testing a new drug, TNG260, combined with an existing cancer treatment, pembrolizumab, in patients with advanced solid tumors that have an STK11 mutation. TNG260 aims to block proteins that help cancer grow, while pembrolizumab boosts the immune system to fight the cancer. Pembrolizumab has been shown to be an effective and safe therapeutic option for various advanced cancers, including endometrial cancer and melanoma. The study will determine the best dose, safety, and effectiveness of this combination.
Recruiting1 award Phase 1 & 2
Disitamab Vedotin + Tucatinib
for Breast Cancer
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV, with or without tucatinib, is for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Recruiting1 award Phase 1 & 26 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UCLA Hematology Oncology - Santa Monica?
UCLA Hematology Oncology - Santa Monica is a medical facility located in Santa Monica, California. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Solid Tumors, Tumors and other specialties. UCLA Hematology Oncology - Santa Monica is involved with conducting 91 clinical trials across 82 conditions. There are 7 research doctors associated with this hospital, such as Zev A. Wainberg, Sara Hurvitz, MD, Jonathan W. Goldman, and Saeed Sadeghi.